rs6518275
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001142854.2(SPATC1L):c.193+2720G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0688 in 152,300 control chromosomes in the GnomAD database, including 1,139 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.069 ( 1139 hom., cov: 33)
Consequence
SPATC1L
NM_001142854.2 intron
NM_001142854.2 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.706
Publications
2 publications found
Genes affected
SPATC1L (HGNC:1298): (spermatogenesis and centriole associated 1 like) Enables identical protein binding activity. Predicted to act upstream of or within several processes, including actin polymerization or depolymerization; positive regulation of cAMP-dependent protein kinase activity; and positive regulation of protein kinase A signaling. Predicted to be located in sperm connecting piece. Predicted to be active in centrosome. [provided by Alliance of Genome Resources, Apr 2022]
SPATC1L Gene-Disease associations (from GenCC):
- hearing loss disorderInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.92).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.231 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SPATC1L | NM_001142854.2 | c.193+2720G>A | intron_variant | Intron 2 of 4 | ENST00000291672.6 | NP_001136326.1 | ||
| SPATC1L | NM_032261.5 | c.-270+4452G>A | intron_variant | Intron 1 of 3 | NP_115637.3 | |||
| SPATC1L | XM_005261188.6 | c.193+2720G>A | intron_variant | Intron 2 of 4 | XP_005261245.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0688 AC: 10468AN: 152182Hom.: 1139 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
10468
AN:
152182
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.0688 AC: 10475AN: 152300Hom.: 1139 Cov.: 33 AF XY: 0.0659 AC XY: 4906AN XY: 74482 show subpopulations
GnomAD4 genome
AF:
AC:
10475
AN:
152300
Hom.:
Cov.:
33
AF XY:
AC XY:
4906
AN XY:
74482
show subpopulations
African (AFR)
AF:
AC:
9754
AN:
41532
American (AMR)
AF:
AC:
476
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
AC:
16
AN:
3472
East Asian (EAS)
AF:
AC:
1
AN:
5188
South Asian (SAS)
AF:
AC:
7
AN:
4828
European-Finnish (FIN)
AF:
AC:
0
AN:
10626
Middle Eastern (MID)
AF:
AC:
6
AN:
294
European-Non Finnish (NFE)
AF:
AC:
98
AN:
68032
Other (OTH)
AF:
AC:
117
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
425
850
1276
1701
2126
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
98
196
294
392
490
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
39
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.